Current Clinical Trials for Hematologic Malignancies

CALGB 10002 - Phase II Study of Rituximab and Short Duration, High Intensity Chemotherapy with G-CSF Support in Previously Untreated Patients with Burkitt Lymphoma/Leukemia

CALGB 100103 - A Phase II Study of Allogeneic Transplant for Older Patients with AML In CRI Using a Non-Myeloablative Preparative Regimen.

CALGB 10403 - An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia

CALGB 10404 - A GENETIC RISK-STRATIFIED, RANDOMIZED PHASE II STUDY OF FOUR FLUDARABINE/ANTIBODY COMBINATIONS FOR PATIENTS WITH SYMPTOMATIC, PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA

CALGB 10502 - Dose Escalation and Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 Years

CALGB 10503 - Phase II Study Of Maintenance Therapy With Decitabine (NSC #127716, IND #50733) Following Standard Induction And Cytogenetic Risk-Adapted Intensification In Previously Untreated Patients With AML Less Than 60 Years

CALGB 10602 - A Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia

CALGB 10603 - Phase III Randomized Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)

CALGB 29801 - Molecular and Cytogenetic Monitoring of CML

CALGB 50303 - Phase III Randomized Study of R-Chop V. Dose-Adjusted Epoch-R (DA-EPOCH-R) with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas

ECOG 2905 - Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia

GCC 0447 - A Phase 1 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, or Saha) In Combination with Cytosine Arabinoside (Ara-C) and Etoposide for Patients with Relapsed and/or Refractory Acute Leukemias, Myelodysplasias and Myeloproliferative Disorders

GCC 0507 - A Phase 1 Study of UCN-01 in Combination With Perifosine in Patients With Relapsed and Refractory Acute Leukemias and High Risk MDS

GCC 0738 - Phase 2 Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA 51 VG Adjuvant and Administered With GM-CSF in Low Risk and Intermediate-1 MDS

GCC 0820 - Bone Marker-Directed Dosing of Zometa (Zoledronic Acid) for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma

GCC 0823 - Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects with Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function.

GCC 0835 - Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous

GCC 0839 - Phase 1/2 Open-Label Study of the Safety and Efficacy of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Refractory Multiple Myeloma

GCC 0851 - Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response. BMT/CTN 0701

GCC 0854 - A Multicenter, Phase II Trial of Non-myeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients with Hematologic Malignancies. BMT/CTN 0603

GCC 0856 - A Multicenter, Open Label Phase I / II Study of CEP-701 (Lestaurtinib) in Adults with Myelofibrosis

GCC 0908 - An Open-Label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients with Advanced Hematological Malignancies

GCC 0911 - Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis

GCC 0922 - Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-cell Lymphomas. NCI Protocol 8064

GCC 0942 - A Multi-center, Phase 2, Single-Arm, Open-Label Exploratory Study of Individually-Optimized Conditioning Using Pharmacokinetics [PK]-directed Dose Adjustment of Once Daily Intravenous Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant in Subjects with Non- Hodgkins Lymphoma and Hodgkins Lymphoma

GCC0706 - Phase I Study of Sirolimus in Acute Myeloid Leukemia

GCC0753 - A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

GCC0754 - A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients With Chronic Myeloid Leukemia (CML) Who Have Failed or Are Intolerant to Tyrosine Kinase Inhibitor Therapy

GCC0799 - A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

GCC0812 - Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as Post-Consolidation Therapy in Adult Patients With Acute Myeloid Leukemia

GCC0844 - P04717 - A Phase 2 Study of SCH 727965 in Subjects with Relapsed and Refractory Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia

S0521 - A Randomized Trial of Maintenance Versus Observation for Patients With Previously Untreated Low And Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III

SWOG 0535 - A Phase II Study of Atra, Arsenic Trioxide And Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia

Email this Page                                                                     Print this Page